Data captured from pediatric patients revealed a relationship between high burden of common infection episodes in early life and increased risk for moderate to severe infections in later childhood.
Tildrakizumab showed significant clinical improvements, with 97.1% achieving Psoriasis Area Severity Index 75 (PASI75) and 82.9% reporting minimal impairment by week 28. The study involved 62 patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback